Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Relapsed/Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia (B-ALL)
Latest Information Update: 17 Oct 2024
At a glance
- Drugs MC 1 50 (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Chongqing Precision Biotech Co., Ltd
- 17 Oct 2024 New trial record